Caisse Bio: Implementing differentiated dividends in 2025, planning to distribute 324 million yuan in cash dividends.

Kaisai Bioscience announced that as of the date of issuing the verification opinion, the number of shares repurchased in the company's repurchase special securities account is 1.2 million shares, accounting for 0.17% of the total share capital. According to regulations, the repurchased shares do not enjoy the right to profit distribution, so differential dividends will be implemented in 2025. The profit distribution plan will be deliberated and approved at the 2025 annual general meeting, with the total share capital minus the shares in the repurchase special account as the base, distributing a cash dividend of 4.50 yuan per 10 shares to all shareholders, without bonus shares or capitalization, intending to distribute a cash dividend of 324 million yuan. Based on the closing price on July 2, 2026, the impact of differential equity distributions on the reference price for ex-rights and ex-dividends is relatively small.